Publication:
Effect of CPAP treatment on adhesion molecules in coronary artery disease with nonsleepy obstructive sleep apnoea: The RICCADSA randomized controlled trial

dc.contributor.coauthorZou, Ding
dc.contributor.coauthorLindberg, Tülay
dc.contributor.coauthorThunstrom, Erik
dc.contributor.departmentKUTTAM (Koç University Research Center for Translational Medicine)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorÇelik, Yeliz
dc.contributor.kuauthorPeker, Yüksel
dc.contributor.kuprofileResearcher
dc.contributor.kuprofileFaculty Member
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.contributor.schoolcollegeinstituteResearch Center
dc.contributor.yokidN/A
dc.contributor.yokid234103
dc.date.accessioned2024-11-09T23:49:09Z
dc.date.issued2020
dc.description.abstractBackground: Enhanced levels of vascular adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) have been associated with obstructive sleep apnoea (OSA). Impact of continuous positive airway pressure (CPAP) treatment on VCAM-1 and ICAM-1 levels in coronary artery disease (CAD) patients with OSA is unclear. Aims and Objectives: We aimed to evaluate whether CPAP therapy would reduce VCAM-1 and ICAM-1 after one year in a revascularized CAD cohort. Methods: This was one of the secondary outcomes of the RICCADSA trial, conducted in Sweden between 2005 and 2013. In all, 210 adults with nonsleepy OSA (apnea-hypopnea index ≥15/h, and Epworth Sleepiness Scale <10) were included. Participants were randomized to CPAP (n=104), or no-CPAP (n=106). Circulating levels of the adhesion molecules were assessed at baseline and after one year. Results: Median VCAM-1 decreased from 1055 to 979 ng/ml (p=0.02) in CPAP group, and from 1062 to 1034 ng/ml (p=0.95) in no-CPAP group. Similarly, median ICAM-1 reduced from 152 to 115 ng/ml (p<0.001) in CPAP group, and from 146 to 127 ng/ml (p=0.001) in no-CPAP group. Change from baseline in median values did not differ significantly between the groups. In a multivariate linear backward regression model, CPAP use (hrs/night) was associated with the decline in VCAM-1 (β=0.16 [95% CI 5.10-88.14], p=0.028), and tended to be significant with the decrease in the ICAM-1 (p=0.08). Conclusions: There was a natural decrease in the VCAM-1 and ICAM-1 values after one year in this CAD cohort with OSA. The magnitude of the decline was associated with increasing CPAP usage.
dc.description.indexedbyWoS
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.volume56
dc.identifier.doi10.1183/13993003.congress-2020.4740
dc.identifier.eissn1399-3003
dc.identifier.issn0903-1936
dc.identifier.quartileQ2
dc.identifier.urihttp://dx.doi.org/10.1183/13993003.congress-2020.4740
dc.identifier.urihttps://hdl.handle.net/20.500.14288/14323
dc.identifier.wos606501408021
dc.languageEnglish
dc.sourceEuropean Respiratory Journal
dc.subjectRespiratory system
dc.titleEffect of CPAP treatment on adhesion molecules in coronary artery disease with nonsleepy obstructive sleep apnoea: The RICCADSA randomized controlled trial
dc.typeMeeting Abstract
dspace.entity.typePublication
local.contributor.authorid0000-0002-4041-4529
local.contributor.authorid0000-0001-9067-6538
local.contributor.kuauthorÇelik, Yeliz
local.contributor.kuauthorPeker, Yüksel
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1Research Center
local.publication.orgunit2KUTTAM (Koç University Research Center for Translational Medicine)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublication91bbe15d-017f-446b-b102-ce755523d939
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscovery91bbe15d-017f-446b-b102-ce755523d939
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublicationd437580f-9309-4ecb-864a-4af58309d287
relation.isParentOrgUnitOfPublication.latestForDiscoveryd437580f-9309-4ecb-864a-4af58309d287

Files